Learn more

MERCK SERONO SA

Overview
  • Total Patents
    867
  • GoodIP Patent Rank
    35,783
  • Filing trend
    ⇩ 50.0%
About

MERCK SERONO SA has a total of 867 patent applications. It decreased the IP activity by 50.0%. Its first patent ever was published in 1992. It filed its patents most often in Australia, EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are SERONO LAB, SK KEMIKALZ KO LTD and SOD CONSEILS RECH APPLIC.

Patent filings per year

Chart showing MERCK SERONO SAs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Quattropani Anna 145
#2 Bombrun Agnes 108
#3 Schwarz Matthias 84
#4 Crosignani Stefano 75
#5 Dorbais Jerome 75
#6 Montagne Cyril 70
#7 Jorand-Lebrun Catherine 63
#8 Pomel Vincent 57
#9 Gaillard Pascale 52
#10 Rueckle Thomas 46

Latest patents

Publication Filing date Title
BR112018013585A2 compound, pharmaceutical composition, method for synthesizing a compound, method for preparing a compound, method for treating or preventing premature labor, method for preventing labor before cesarean delivery, method for treating or preventing dysmenorrhea and kit
US9447055B1 α-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereof
AU2014200178A1 The Puro-DHFR quadrifunctional marker and its use in protein production
CN103597073A Low fucose cell lines and uses thereof
IL217216D0 Low fucose cell lins and uses thereof
AU2011265521A1 JNK inhibitors for the treatment of endometreosis
WO2012085911A1 Membrane bound reporter molecules and their use in cell sorting
CN103429585A Indazolyl triazole derivatives as irak inhibitors
AU2011254072A1 Pyrrolidine derivatives as prostaglandin modulators
WO2012066089A1 Antibody with specificity for gm-csf (ii)
AU2011331162A1 Antibody with specificity for GM-CSF (I)
AU2011235982A1 Use of IL-6-Type Cytokines for Maturation of Oocytes
WO2012028633A1 Genomic markers for prediction of long-term response to growth hormone (gh) therapy
WO2012022740A1 Combination treatment of multiple sclerosis
BR112013000041A2 5- (biphenyl-4-yl) -3-phenyl-1,2,4-oxadiazolyl derivatives as binders at sphingosine 1-phosphate (sip) receptors
TW201206429A Substituted oxadiazole derivatives
WO2011117267A1 Cladribine treatment of multiple sclerosis in patient groups defined by genotype
IL211583D0 Low fucose cell lines and uses thereof
WO2011098456A1 Safinamide in the treatment of dyskinesia
MX2012005791A Humanized antibodies against human il-22ra.